Who are Usual brand cigar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nicotine Patch and Nicotine Lozenge, Galantamine (Reminyl), Mailed nicotine replacement therapy, Pre-Quit Nicotine Gum, Nicotine replacement, Extended Duration Combination NRT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/usual-brand-cigar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Usual brand cigar — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Usual brand cigar (Usual brand cigar) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed nicotinic acetylcholine receptors Small molecule Live · refreshed every 30 min

Target snapshot

Usual brand cigar (Usual brand cigar) — Ohio State University Comprehensive Cancer Center. Usual brand cigar is a tobacco product that contains nicotine, which acts on nicotinic acetylcholine receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Usual brand cigar TARGET	Usual brand cigar	Ohio State University Comprehensive Cancer Center	marketed		nicotinic acetylcholine receptors
Nicotine Patch and Nicotine Lozenge	Nicotine Patch and Nicotine Lozenge	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Galantamine (Reminyl)	Galantamine (Reminyl)	Janssen-Cilag Pty Ltd	marketed	Acetylcholinesterase inhibitor with nicotinic receptor modulation	Acetylcholinesterase; nicotinic acetylcholine receptors
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Pre-Quit Nicotine Gum	Pre-Quit Nicotine Gum	University of Wisconsin, Madison	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Nicotine replacement	Nicotine replacement	Instituto Fernandes Figueira	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Extended Duration Combination NRT	Extended Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (combination)	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Usual brand cigar — Competitive Intelligence Brief. https://druglandscape.com/ci/usual-brand-cigar. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab